DHGF(600257)2023-07-21 16:00Financial Performance - The company's operating revenue for 2022 was CNY 1,094,712,820.42, a decrease of 15.29% compared to CNY 1,292,312,436.98 in 2021[23] - The net profit attributable to shareholders of the listed company was a loss of CNY 71,495,117.40, an improvement of 60.31% from a loss of CNY 180,118,858.50 in the previous year[23] - The net cash flow from operating activities was CNY 97,866,143.08, showing a slight increase of 1.50% compared to CNY 96,420,908.67 in 2021[23] - Total assets at the end of 2022 were CNY 2,161,876,319.04, a decrease of 7.63% from CNY 2,340,424,356.56 at the end of 2021[23] - The net assets attributable to shareholders of the listed company decreased by 7.34% to CNY 879,723,654.23 from CNY 949,434,742.91 in 2021[23] - Basic earnings per share improved by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - Diluted earnings per share also increased by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - The weighted average return on equity improved by 9.38 percentage points from -17.2% in 2021 to -7.82% in 2022[24] - The company reported a net loss of CNY 219,125,049.68 in 2022, compared to a net loss of CNY 147,629,932.28 in 2021, indicating a worsening of approximately 48.4%[195] Business Operations - The company faced a decline in revenue from its main business, with a decrease of 15.51% in the revenue excluding non-main business income[23] - The company is focusing on health products and health services, aiming to upgrade to a comprehensive health industry[33] - The aquaculture division is enhancing brand marketing and optimizing product structure based on high-quality seedling breeding and ecological balance[33] - The company is committed to ecological aquaculture, promoting the production of safe and healthy organic freshwater products[33] - The company plans to continue expanding its sales channels and improving its product structure in the health sector[33] - The revenue from frozen and chilled products (including prepared dishes) increased by approximately 13% year-on-year in 2022[34] - The company has established a pre-prepared dish industrial park with a total area of 46,700 square meters, including a cold storage area of over 1,900 square meters, expected to increase production capacity by 15,700 tons[34] - The company has adjusted its product structure to focus on the development of sauce-flavored liquor, with an increasing proportion of mid-range and high-end series liquor products[37] - The health medical service division has implemented a quality management monitoring system to enhance medical service quality and improve hospital reputation[38] - The company has established a rehabilitation hospital and nursing home in Hangzhou, which officially opened in August 2022, aligning with national health strategies[40] Market Trends and Opportunities - The pre-made dishes market in China is expected to exceed 800 billion yuan by 2025, with the pre-made dish market for sauerkraut fish projected to reach 1.69 billion yuan, highlighting the growth potential in the aquatic pre-made dish sector[46] - The aquatic pre-made dish market is becoming a new growth point for the aquatic industry, driven by changing consumer habits and the demand for convenient, healthy food options[46] - The number of rehabilitation medical discharges in China reached 4.42 million in 2021, with a five-year compound growth rate of 8.81%, indicating a growing demand for rehabilitation services[50] - The Chinese rehabilitation medical market is expected to exceed 220 billion yuan by 2025, driven by an aging population and increasing rehabilitation needs[50] Corporate Governance - The company has established a governance structure that includes a board of directors with 5 members, including 2 independent directors[91] - The company held 9 board meetings and 5 supervisory meetings during the reporting period[92] - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, with a total of 22 proposals reviewed and approved[94] - The total pre-tax remuneration for the chairman and general manager was CNY 798,700, while the vice chairman received CNY 332,200[96] - The company has maintained a consistent management team with no changes in shareholding reported for the year[96] Financial Health and Investments - The company's cash and cash equivalents decreased by 32.10% to ¥231,449,101.93, primarily due to the repayment of short-term loans[78] - The company reported a significant reduction in short-term borrowings by 16.04% to ¥263,806,070.52, reflecting repayment efforts[79] - The company has engaged in bank wealth management with a total amount of 94,260,000 RMB, with no overdue amounts[166] - The company has a rental payment obligation totaling 342,873,165.3 RMB, after deducting payments made in 2021 and 2022[163] - The company has ongoing guarantees for rental payments amounting to 313,574,275.7 RMB for two hospitals[162] Research and Development - Research and development expenses increased by 160.99% to CNY 947.66 thousand, reflecting a focus on innovation[61] - Total R&D investment accounted for 0.08% of operating revenue, with all R&D expenses being expensed rather than capitalized[74] - The company has implemented a diversified training program to enhance employee skills and core competitiveness, resulting in a significant increase in the number of employees obtaining intermediate and senior professional titles in 2022[120] Social Responsibility - The company contributed a total of CNY 25.64 million to various charitable projects, including CNY 17 million in cash donations and CNY 8.64 million in material donations[129] - The total donation for rural revitalization and poverty alleviation projects amounted to CNY 32.65 million, with specific contributions of CNY 20 million to Yanglouping Village and CNY 10 million to Dongxi West Village[130] - The company has actively participated in social responsibility initiatives, including environmental protection and community support[128] Strategic Changes and Future Plans - The company has acknowledged potential risks in its future plans and development strategies, advising investors to be cautious[6] - The company plans to issue non-public A-shares in 2022, with a feasibility analysis for the use of raised funds[108] - The company is focusing on new product development and technological advancements to drive future growth[171] - The overall financial performance indicates a positive outlook for the upcoming fiscal year, with strategic initiatives in place[171]